| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Pregabalin |
| Brand | Lyrica® |
| Indication | For the treatment of peripheral and central neuropathic pain, generalised anxiety disorder and as adjunctive therapy for epilepsy. |
| Assessment Process | |
| Full submission received from Applicant | 30/09/2013 |
| NCPE assessment completed | 25/10/2013 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE do not recommend pregabalin as a cost effective treatment for neuropathic pain.
| Assessment Status | Full HTA Re-assessment |
| Full re-submission received from Applicant | 10/11/2014 |
| NCPE assessment completed | 12/06/2015 |
| NCPE assessment outcome | Currently reimbursed – cost effective under certain assumptions. |
